<DOC>
	<DOCNO>NCT01228422</DOCNO>
	<brief_summary>The aim verify Pharmacokinetics Pharmacodynamics alpha interferon product-2A - Blausiegel , take comparator drug product Roferon ® A ( interferon alpha-2A - Roche Laboratory ) .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics Interferon Alpha 2A</brief_title>
	<detailed_description>The Interferons ( IFNs ) group cytokine produce vertebrate response various stimulus , include presence foreign nucleic acid body , bacteria , tumor cell viral antigen . These protein significant share immunomodulatory , antiproliferative antiviral drug , first line defense body . Once produce , IFNs block viral replication , maximize lytic activity natural killer cell , increase expression MHC class I cell infected virus induce development Th1 cell The production interferon alpha-2A hold biotechnology establishment chain DNA producer interferon alpha-2a chain original DNA bacterium , allow bacteria produce drug industrial scale . In process synthesis , 165 amino acid part molecule change order reduction activity change property . Due fact , biological medicinal consider , especially manufacture genetic engineering , need prove clinical activity market . In case interferon , consequence use product without activity compare treat patient Hepatitis C lead serious health complication . It therefore necessary prove clinical activity pharmacokinetics clinical efficacy . The sponsor study aim end renewal registration interferon alpha-2A Ministry Health So study evaluate Pharmacokinetics Pharmacodynamics interferon alpha-2a may allow future medicine use year patient hepatitis C , without risk health , besides already know inherent treatment interferon .</detailed_description>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Accepting End Free Informed Consent ; Research subject male , age 18 55 year ; Research subject body mass index ≥ 19 ≤ 30 ; Be consider healthy , analysis medical history , medical examination laboratory test within normal range . Results laboratory test outside value consider acceptable accordance criterion medical evaluator ; Having participate experimental study ingest experimental drug last three month start study ; Have make regular use medication past 4 week precede start study make use medication week start study ; Have hospitalize reason , 8 week start study ; Present history abuse alcohol , drug medication , ingest alcohol within 48 hour prior period stay ; Have history liver disease , renal , pulmonary , gastrointestinal , hematological psychiatric ; Present pressure change cause require pharmacological treatment ; present history myocardial infarction , angina / heart failure ; Have donate lose 450 ml blood three month precede study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Will study 24 subject divide Research 2 parallel group</keyword>
	<keyword>The treatment dose 3MUI alpha interferon 2nd</keyword>
	<keyword>There collection blood time : 0 , 2 , 4 , 6 , 8 , 10 , 12 , 16 , 24 , 36 , 48 , 72 96 hour .</keyword>
	<keyword>The volunteer hospitalize 24 hour .</keyword>
	<keyword>Will measure label AUC , Tmax , Cmax , neopterin beta2-microglobulin</keyword>
</DOC>